Tempero Bio Secures Major Funding to Tackle Substance Use Disorders
Tempero Bio Secures Major Funding to Tackle Substance Use Disorders
Tempero Bio, a biopharmaceutical company known for its commitment to transforming the landscape of substance use disorder treatments, has successfully closed a significant funding round. The newly acquired funding of $70 million is earmarked to propel its lead candidate, TMP-301, into Phase 2 clinical trials aimed at treating alcohol and cocaine use disorders.
Funding and Plans for Clinical Trials
This Series B financing round was driven by the venture capital firm 8VC, with enthusiastic contributions from Aditum Bio, Khosla Ventures, and several other investors. The funds will not only advance TMP-301 through the trials but will also support essential Phase 3 preclinical studies for additional therapeutic indications.
"Substance use disorders have a profound impact on millions, with urgent demands for safer and more effective treatments existing now more than ever," stated Dr. Ricardo Dolmetsch, President and Chief Scientific Officer of Tempero Bio. He emphasized the innovative nature of TMP-301, which is designed to tackle the biological underpinnings of addiction and prevent patient relapses.
Understanding TMP-301's Mechanism
TMP-301 operates as a metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator, a class of compounds that potentially reduces cravings and withdrawal symptoms. Its development is particularly promising, as it has shown effectiveness in preclinical models for various substance use disorders, including alcohol, cocaine, and opiate dependencies. The candidate has already been evaluated in Phase 1 trials with over 80 healthy participants, revealing a favorable safety profile and confirming significant receptor interaction through advanced imaging techniques.
Clinical Studies in Progress
Tempero Bio is actively working to establish TMP-301’s efficacy through two pivotal clinical studies. The first Phase 2 trial aims to validate its effectiveness and safety among patients suffering from alcohol use disorder. Additionally, a drug-drug interaction study is evaluating TMP-301 in individuals who use cocaine, subsequently leading to a Phase 2 trial for cocaine addiction upon completion of this initial study.
Combatting the Addiction Epidemic
The addiction crisis continues to pose a serious challenge to public health. According to recent statistics, approximately 28 million Americans are dealing with alcohol use disorder, while 29 million face drug use disorders. Alarmingly, around 1.3 million individuals are battling cocaine use disorder without FDA-approved medications available for treatment.
Despite these daunting numbers, evidence indicates an increasing willingness among individuals to seek treatment, with nearly 13 million pursuing help in 2023. This underscores the pressing need for innovative and effective therapeutic options, aligning with Tempero Bio's mission to fill this therapeutic gap for those in need.
Leadership Addition at Tempero Bio
Tempero Bio is thrilled to welcome Dr. John Wagner as the new Chief Medical Officer. Dr. Wagner brings immense expertise, boasting over 20 years in drug development, including the success of more than 150 first-in-human clinical trials. His impressive track record includes pivotal roles in bringing numerous successful therapies to the commercial market. Before this appointment, Dr. Wagner served in senior positions at leading pharmaceutical companies, such as Takeda and Merck, and made impactful contributions at Koneksa Health and Cygnal Therapeutics.
About Tempero Bio
Tempero Bio stands at the forefront of developing groundbreaking treatments for substance use disorders, which are chronic illnesses often resistant to conventional therapies. As part of the Aditum Bio portfolio, the company is intensely focused on scientifically driven approaches to redefine treatment methodologies for these conditions.
Frequently Asked Questions
What is the main goal of the funding secured by Tempero Bio?
The funding aims to advance TMP-301 through Phase 2 clinical trials for alcohol and cocaine use disorders.
What is TMP-301?
TMP-301 is a next-generation metabotropic glutamate receptor 5 negative allosteric modulator, designed to help prevent relapse in addiction treatments.
How will the funding be utilized?
The financing will support Phase 2 trials, preclinical studies, and then advance to Phase 3 enabling activities for TMP-301.
What is the significance of the clinical trials for TMP-301?
These trials aim to test the safety and efficacy of TMP-301 among patients with alcohol and cocaine use disorders.
Who is leading Tempero Bio's scientific efforts?
Dr. Ricardo Dolmetsch, serving as the President and Chief Scientific Officer, leads the scientific initiatives at Tempero Bio.
About The Author
Contact Addison Perry privately here. Or send an email with ATTN: Addison Perry as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.